Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12068737 | 0.84 | L3MBTL1 (0.56) | L3MBTL1TDP1 | |
| SCHEMBL28393209 | 0.83 | L3MBTL1 (0.47) | L3MBTL1HDAC8HSD17B10LMNAMAPT | |
| SCHEMBL17397329 | 0.80 | L3MBTL1 (0.50) | L3MBTL1ADORA2AADORA1HSD17B10 | |
| SCHEMBL6264956 | 0.78 | L3MBTL1 (0.65) | L3MBTL1CREBBPCYP19A1ADORA2AADORA1 | |
| SCHEMBL13075646 | 0.78 | L3MBTL1 (0.59) | L3MBTL1CREBBPCYP19A1ADORA2AADORA1 | |
| SCHEMBL671859 | 0.78 | L3MBTL1 (0.50) | L3MBTL1CYP19A1ADORA2AADORA1SIGMAR1 | |
| SCHEMBL28419208 | 0.78 | CYP19A1 (0.54) | CYP19A1 | |
| SCHEMBL3518605 | 0.78 | HSP90AA1 (0.46) | L3MBTL1POLBHSD17B10LMNAMAPT | |
| SCHEMBL10283891 | 0.77 | L3MBTL1 (0.62) | L3MBTL1CREBBPCYP19A1ADORA2AADORA1 | |
| SCHEMBL2413457 | 0.77 | L3MBTL1 (0.62) | L3MBTL1CREBBPCYP19A1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139546-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2015-09-22 | — | — | US | claimed |
| US-20110207748-A1 | Tri-Aryl/Heteroaromatic Cannabinoids and Use Thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-08-25 | — | — | US | claimed |
| US-7888365-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-02-15 | — | — | US | claimed |
| CN-101668425-A | Tri-aryl/heteroaroaromatic cannabinoids and use thereof | UNIV TENNESSEE RES FOUNDATION | 2010-03-10 | — | — | CN | claimed |
| EP-2131655-A2 | TRI-ARYL/HETEROAROMATIC CANNABINOIDS AND USE THEREOF | The University of Tennessee Research Foundation (US) | 2009-12-16 | — | — | EP | claimed |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-09-25 | — | — | US | claimed |
| WO-2008109027-A2 | TRI-ARYL/HETEROAROAROMATIC CANNABINOIDS AND USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) | 2008-09-12 | — | — | WO | claimed |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2025129116-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2004011010-A1 | MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1192169-B1 | C-PYRAZOLE A2A RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2003-05-14 | — | — | EP | disclosed |
| CN-1358189-A | C-2A pyrazole A2A receptor agonists | CV THERAPEUTICS INC (US) | 2002-07-10 | — | — | CN | disclosed |
| EP-1192169-A2 | C-PYRAZOLE A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-20010018428-A1 | C-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2001-08-30 | — | — | US | disclosed |
| US-6214807-B1 | IMAGES AND CARDIOVASCULAR DISORDERS | CV THERAPEUTICS, INC. | 2001-04-10 | — | — | US | disclosed |
| WO-2000078778-A2 | C-PYRAZOLE A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | L3MBTL1 595/4885CREBBP 363/4885CYP19A1 4459/4885 |
| US-20010018428-A1 | C-pyrazole A2A receptor agonists | ADORA2A, ADORA3, ADORA1 | L3MBTL1 4669/4885CREBBP 2300/4885CYP19A1 2077/4885 |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | SMARCA2, SMARCE1, SMARCA1 | L3MBTL1 3239/4885CREBBP 1433/4885CYP19A1 2115/4885 |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | CNR1, CNR2, OPRM1 | L3MBTL1 4553/4885CREBBP 936/4885CYP19A1 395/4885 |
| US-20110207748-A1 | Tri-Aryl/Heteroaromatic Cannabinoids and Use Thereof | CNR1, CNR2, OPRM1 | L3MBTL1 4553/4885CREBBP 936/4885CYP19A1 395/4885 |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP3, DPP7, DPP9 | L3MBTL1 674/4885CREBBP 4399/4885CYP19A1 2182/4885 |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | L3MBTL1 595/4885CREBBP 363/4885CYP19A1 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.